Department of Obstetrics and Gynecology, Sapporo Medical University School of Medicine, 291 Nishi 16-chome, Minami 1-jo, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Department of Pathology, Sapporo Medical University School of Medicine, Nishi 17-chome, Minami 1-jo, Chuo-ku, Sapporo, Hokkaido, 060-8556, Japan.
Med Mol Morphol. 2022 Dec;55(4):275-282. doi: 10.1007/s00795-022-00329-6. Epub 2022 Jul 25.
Desmoplastic reaction (DR) and inflammation are significant pathological manifestations of tumorigenesis in several cancers. However, the correlation between these stromal reactions and cervical adenocarcinoma has been poorly documented. This investigation elucidated whether DR is a prognostic indicator in early cervical adenocarcinoma patients. Fifty-nine patients with early stage cervical adenocarcinoma (stages I/II) were included in the study. DR was divided into three groups, mature, intermediate, and immature, based on the presence of myxoid stroma and hyalinized keloid-like collagen. Inflammatory cell responses were classified as mild, moderate, and severe. Those stromal reactions were separately evaluated in the invasion front stroma and intratumoral stroma. In both the intratumor and invasion front stroma, intermediate/immature DR was correlated with tumor size, T stage, N stage, lymphovascular invasion, and parametrial infiltration (p < 0.001 to p < 0.05). In addition, in the intratumoral stroma, intermediate/immature DR led to short relapse-free survival and overall survival (p < 0.001). In the invasion front stroma, inflammatory cell responses were associated with DR immaturity and FIGO stage (p < 0.01). These results suggest that the classification of DR maturity is a potential prognostic biomarker in early stage cervical adenocarcinoma patients. DR can be evaluated by routine H&E staining without immunohistochemistry, making it convenient and economical in clinical practice.
促结缔组织增生反应和炎症是多种癌症发生肿瘤的重要病理表现。然而,这些基质反应与宫颈腺癌之间的相关性尚未得到充分的记录。本研究探讨了促结缔组织增生反应是否是早期宫颈腺癌患者的预后指标。本研究纳入了 59 例早期宫颈腺癌(I/II 期)患者。根据黏液样基质和玻璃样瘢痕样胶原的存在,将促结缔组织增生反应分为成熟型、中间型和不成熟型。根据炎症细胞反应的程度,将其分为轻度、中度和重度。分别在肿瘤边缘间质和肿瘤内间质中评估这些基质反应。在肿瘤边缘间质和肿瘤内间质中,中间/不成熟型促结缔组织增生反应与肿瘤大小、T 分期、N 分期、脉管侵犯和宫旁浸润相关(p<0.001 至 p<0.05)。此外,在肿瘤内间质中,中间/不成熟型促结缔组织增生反应与较短的无复发生存期和总生存期相关(p<0.001)。在肿瘤边缘间质中,炎症细胞反应与促结缔组织增生反应的不成熟和 FIGO 分期相关(p<0.01)。这些结果表明,促结缔组织增生反应成熟度的分类是早期宫颈腺癌患者潜在的预后生物标志物。促结缔组织增生反应可以通过常规的 H&E 染色进行评估,而无需免疫组织化学染色,这在临床实践中既方便又经济。